LLY

976.43

-1.67%↓

JNJ

222.34

-0.53%↓

ABBV

202.95

-0.89%↓

UNH

367.82

+0.13%↑

AZN

182.55

-1.35%↓

LLY

976.43

-1.67%↓

JNJ

222.34

-0.53%↓

ABBV

202.95

-0.89%↓

UNH

367.82

+0.13%↑

AZN

182.55

-1.35%↓

LLY

976.43

-1.67%↓

JNJ

222.34

-0.53%↓

ABBV

202.95

-0.89%↓

UNH

367.82

+0.13%↑

AZN

182.55

-1.35%↓

LLY

976.43

-1.67%↓

JNJ

222.34

-0.53%↓

ABBV

202.95

-0.89%↓

UNH

367.82

+0.13%↑

AZN

182.55

-1.35%↓

LLY

976.43

-1.67%↓

JNJ

222.34

-0.53%↓

ABBV

202.95

-0.89%↓

UNH

367.82

+0.13%↑

AZN

182.55

-1.35%↓

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Отворен

3.19 -1.24

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.14

Максимум

3.2800000000000002

Ключови измерители
By Trading Economics
Приходи	1.3M -3M
Продажби	100K 100K
Марж на печалбата	-2,954
Служители	21

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-16M 23M
Предишно отваряне	4.43
Предишно затваряне	3.19

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.05.2026 г., 23:41 ч. UTC

Печалби

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6.05.2026 г., 21:40 ч. UTC

Печалби

Nutrien Logs Higher Profit, Sales Growth in 1Q

6.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6.05.2026 г., 23:13 ч. UTC

Печалби

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6.05.2026 г., 23:13 ч. UTC

Печалби

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6.05.2026 г., 23:12 ч. UTC

Печалби

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6.05.2026 г., 23:11 ч. UTC

Печалби

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6.05.2026 г., 23:11 ч. UTC

Печалби

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6.05.2026 г., 23:07 ч. UTC

Печалби

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6.05.2026 г., 23:06 ч. UTC

Печалби

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6.05.2026 г., 23:06 ч. UTC

Печалби

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6.05.2026 г., 23:05 ч. UTC

Печалби

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6.05.2026 г., 23:04 ч. UTC

Печалби

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6.05.2026 г., 22:50 ч. UTC

Печалби

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6.05.2026 г., 22:25 ч. UTC

Пазарно говорене

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6.05.2026 г., 22:11 ч. UTC

Печалби

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6.05.2026 г., 22:11 ч. UTC

Печалби

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6.05.2026 г., 22:05 ч. UTC

Пазарно говорене

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6.05.2026 г., 21:58 ч. UTC

Печалби

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6.05.2026 г., 21:47 ч. UTC

Пазарно говорене

Печалби

Costco Posts 13% Sales Growth in April -- Market Talk

6.05.2026 г., 21:46 ч. UTC

Печалби

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6.05.2026 г., 21:40 ч. UTC

Печалби

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6.05.2026 г., 21:35 ч. UTC

Пазарно говорене

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6.05.2026 г., 21:32 ч. UTC

Горещи акции

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6.05.2026 г., 21:29 ч. UTC

Печалби

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Печалба преди облагане с данъци

Продажби

Оперативна печалба

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.